46 results about "Release pattern" patented technology

The present invention relates to an orally available galenics formulation of Valproic Acid or derivatives thereof exhibiting a specific bi-phasic pharmacokinetic profile optimized for maximum inhibition of histone deacetylases in a therapeutic setting. This specific galenics formulation is designed for the treatment of malignant diseases and diseases associated with hypoacetylation of histones or in which induction of hyperacetylation has a beneficial effect, e.g., by induction of differentiation and/or apoptosis. Due to the bi-phasic release pattern the resulting pharmacokinetic profile is able to inhibit HDAC target enzymes most efficiently and to subsequently induce histone hyperacetylation in a rapid as well as a long-lasting fashion. This profile secures the efficient modulation of a desired target gene expression profile which contributes to the therapeutic benefit.

The present invention relates to a method and apparatus for recognizing a motion pattern formed by a continued contact surface. A method for recognizing a motion patter according to an embodiment of the invention may comprise receiving a motion pattern as input from a user, comparing pattern information of the motion pattern with pattern information of a preset release pattern, and determining a mismatch level of the motion pattern according to the comparison result. According to an embodiment of the invention, if an inputted motion pattern does not match the preset release pattern, the degree of mismatch is determined with different levels, to respond in various ways other than simply maintaining the locked state.

A drug formulation is disclosed comprising granules having a substrate and a coating, said granule substrate comprising a solubilizing surfactant or a low solubility therapeutic drug, or both, and said granule coating comprising a hydrophilic polymer. Also disclosed is a drug formulation consisting of a tablet core made by mechanical compression, wherein said tablet core comprises granules having a substrate and a coating, said granule substrate comprising a solubilizing surfactant or a low solubility therapeutic drug, or both, and said granule coating comprising a hydrophilic polymer. Also disclosed is a dosage form for oral administration of topiramate, comprising a tablet core and an osmotic delivery system. Methods for controlling topiramate release patterns by altering the composition of the topiramate dosage form are also disclosed.

The invention discloses a method, a device and a system for providing road condition information, relates to the field of the processing and application of the road condition information, and is used for avoiding repetitive inquiry operation in the process of acquiring road condition information for a user. The method for providing the road condition information comprises the steps of: viewing ordered information of a user, wherein the ordered information comprises a release time, a release pattern, position information and road condition time; acquiring the road condition information relevant to the position information at the road condition time; and providing the road condition information for the user by utilizing the release pattern when the release time is reached. The method, the device and the system for providing road condition information disclosed by the invention are suitable for the regular acquisition of traffic road condition information for the user.

The present invention relates to a controlled-release niacin formulation. In particular, the present invention relates to a controlled-release niacin formulation, comprising niacin; hydroxypropyl methylcellulose; and a carboxyvinyl polymer, in which the carboxyvinyl polymer and hydroxypropyl methylcellulose are contained in a predetermined weight ratio, and to a preparation method thereof.

The controlled-release niacin formulation according to the present invention maintains its matrix shape until completion of release, and maintains its release pattern without fluctuation for a desired time period, unlike a commercial formulation. In particular, since niacin formulations are used for long-term treatment of hyperlipidemia, the controlled-release niacin formulation of the present invention, capable of maintaining effective blood concentration and high stability for a long period of time, is very useful.

A method for the writing and erasing of a non-volatile memory area, in which after error-free writing of the memory area, at least one release pattern is written into a predetermined subarea of the memory area. To be able to reliably ascertain aborted erase operations, prior to the erase operation, invalidity patterns are written into two further subareas of the memory area, the subareas provided for this enclosing those subareas reserved for the release patterns. The presence (in part) of invalidity patterns indicates an erase operation not ended correctly. The method can be used advantageously in controllers having non-volatile memories.

A hologram laminate and a hologram label allow traces of separation of the hologram to be clearly left on both the adherend and the hologram label and hence makes it possible to prevent reuse of the hologram and is excellent in graphical design function and suitable for certification purposes. The hologram laminate has a colored layer, a release pattern, a transparent film, a hologram layer and a surface protective layer laminated on an adherend in the order mentioned. The hologram layer includes a volume hologram layer and a relief hologram layer having a transparent thin-film layer over the surface of a relief interference fringe pattern. When the hologram is separated between the adherend and the transparent film, the colored layer is left on the adherend in a pattern corresponding to the release pattern.

A device that delivers one or more substances into a vaginal lumen according to one of a plurality of release patterns. The device comprises a supporting structure, substance dispensers, and/or coupling elements which are configured to release one or more substances, for example, drugs, in manner designed to optimize treatment of one or more medical conditions.

The invention provides a hypnotic double-layer controlled release tablet, comprising a rapid-release layer and a slow-release layer, wherein the rapid-release layer is provided with pores which are filled with rapid-release particles; the rapid-release layer and the rapid-release particles are composed of hypnotic drug and pharmaceutical excipients; the slow-release layer is composed of a hypnotic drug, a slow-release material and pharmaceutical excipients. The hypnotic double-layer controlled release tablet has the following technical effects that 1) the physical stability of the double-layer tablet provided by the invention is better than that of the common double-layer table, which is advantageous for storage and transportation, and 2) a dissolution test detects that the disintegration time limit of the rapid-release layer of the double-layer tablet provided by the invention ranges from 20 seconds to 30 seconds; and the slow-release layer is in a zero-order release pattern, and therefore the effectiveness and safety of medication for a patient are greatly improved. In the preparation process of the double-layer tablet, the rapid-release particles fill in the pores. The drug release pattern of combined rapid release and slow release guarantees that the rapid-release layer is disintegrated rapidly after the drug is taken; as a result, the blood concentration is capable of quickly reaching the therapeutic window range; the slow-release layer is slowly released so that the therapeutic action is maintained for a long period of time and toxic and side effects are effectively controlled.

The invention discloses a precise information releasing system and method based on internet, which comprises the following parts: information gathering unit, information analyzing unit, information releasing unit, wherein the information gathering unit is used to gather internet access data of user; the information analyzing unit proceeds statistical analysis for the internet access data gathered by the information gathering unit, which builds the access rule set and user set; the information releasing unit affirms the corresponding user to rule element according to the released information, which proceeds automatic release for directional information without assembling random realizing information at user terminal; when the releasing information doesn' t exist, the normal internet surf is not influenced with different releasing patterns according to different information and user characters.

A gaming device includes a release pattern prediction section which determines a prediction release pattern for the release pattern of the flying object to be released by the first personified character by selecting one of the plurality of release patterns stored in the release pattern storing section based on a selecting operation by a user operating the second personified character; and a difficulty adjustment section, which compares the release pattern determined with the prediction release pattern, and reduces the difficulty for the second character to hit back the flying object released by the first character when the release pattern determined and the prediction release pattern match.

The invention belongs to the field of medicinal preparation and specifically provides a posaconazole double-layer osmotic pump controlled release tablet and a preparation method thereof. The tablet comprises a tablet core and a semipermeable controlled release film. The tablet core comprises a drug containing layer and a boosting layer. The drug containing layer is located inside the controlled release film which is provided with a drug releasing hole. The boosting layer is located inside the controlled release film at a place far away from the drug releasing hole. One end of the water-permeable controlled release film is provided with one or more drug releasing holes. The release curve of the preparation drug shows a zero-order release pattern, and thus the problem of drug resistance caused by long-term use of posaconazole dosage forms on the market is solved. Besides, the problems that the preparation technology is complex, the preparation cost is high, and the drug is unsuitable for industrialized mass production due to the adoption of a hot-melt extrusion technology are solved. Simultaneously, the in vivo-in vitro correlation of the drug is better ensured and the clinical monitoring of plasma concentration is better facilitated.

The invention discloses a building thermal environment control modeling method based on physical properties. The building thermal environment control modeling method determines an hourly thermal environment model of a building through analyzing period outdoor air temperature, solar scattering direct radiation intensity, solar scattering radiation intensity, a wall body heat-storage-release pattern and indoor disturbance, establishes a draught fan coil pipe model through analyzing a heat-releasing pattern of the indoor draught fan coil pipe, establishes the thermal environment control model through analyzing two parts, solves relations between indoor temperature and other influence factors through laplace's transformation, and finally chooses a control variable to control and enables indoor temperature to maintain in a reasonable range. The building thermal environment control modeling method establishes a model on the basis of architectural thermal engineering, combines with thermal engineering characteristics of the draught fan coil pipe, can more accurately describe dynamic characteristics of the architecture thermal environment and provides a model support for subsequent control.

The invention discloses a method of making a self-aligned MEMS piezoresistive accelerometer, comprising the following steps: making a cavity at the bottom of a silicon substrate through a KOH etching process; growing an oxide layer and a silicon nitride layer on the top of the silicon substrate in sequence from bottom to top; making a piezoresistive pattern and a structure release pattern on the silicon nitride layer at the same time through a lithography process, and etching the silicon nitride layer at the piezoresistive pattern and at the structure release pattern; etching the oxide layer at the piezoresistive pattern, and forming a piezoresistor through an injecting process and an annealing process; etching the oxide layer at the structure release pattern to form a structure release area; deeply etching the silicon substrate in the structure release area to form a movable structure, thus getting an MEMS piezoresistive accelerometer. The piezoresistive pattern and the structure release pattern are formed in the same lithography process. There is no need for equipment to carry out alignment in the machining process. Self-alignment of the piezoresistor and a device structure is realized. Thus, the symmetry of devices is improved, error caused by position deviation of the piezoresistor is reduced, and the performance of devices is improved.

The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.

The invention relates to a contraceptive medicament preparation containing gestodene, which is dosed through natural orifice of human beings or mammals or through transdermal or subcutaneous administration. The gestodene is in a zero order release pattern. The contraceptive medicament preparation contains 0.0005 mg to 0.100 mg of gestodene of daily dose, and one or more kinds of pharmaceutical acceptable excipient or carriers. The contraceptive medicament preparation is characterized in that the gestodene is a crystal or powders with the weight specific surface area more than 100 cm2/g. The minimal distance between the geometric center of the crystal with more than or equal to 70% of weight proportion and the surface of the preparation is less than or equal to 5 mm. The minimal distance between the geometric center of the powders with more than or equal to 70% of weight proportion and the surface of the preparation is less than or equal to 5 mm. The contraceptive medicinal preparation contains 0.005 mg to 0.050 mg ethinyloestradiol of daily dose. In the invention, the distribution characteristics of the size and the design of the drug is selected, the drug can be in a better zero order release pattern, and the cumulative release rate is higher.

Disclosed is an array substrate including: a metal pattern and an electrically conductive pattern formed sequentially on a base substrate, the electrically conductive pattern being insulated from the metal pattern; and a static charge releasing pattern formed in a same layer as the electrically conductive pattern lies and formed by a same material as the electrically conductive pattern, wherein the static charge releasing pattern is insulated from the electrically conductive pattern and electrically connected with the metal pattern.

An intrauterine device having at least one first pharmaceutically active ingredient and at least one first layer made of at least a first polymeric material, wherein between about 10 and about 60 v/v % of at least one particulate material is dispersed and/or incorporated in the first polymeric material. The presence of the particulate material will reduce the porosity of the polymer or otherwise obstruct the diffusion of the pharmaceutically active ingredient being released, thereby slowing its rate of release. In this way, it is possible to regulate the release rate and/or initial burst of the device, simply by adjusting the amount of particles/particulate material in the first layer, instead of having to adapt the size of the device to the desired release pattern, which requires expensive changes in production equipment and manufacturing processes.